Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Promotes Forelimb Functional Recovery after Cervical Spinal Cord Injury.
Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Promotes Forelimb Functional Recovery after Cervical Spinal Cord Injury.
复制标题
DOI：
10.3390/cells11172765
复制
发表时间：
2022-09-05
期刊：
影响因子：
6
通讯作者：
Cao, Qilin
中科院分区：
文献类型：
--
作者：
Zheng, Yiyan;Gallegos, Chrystine M.;Xue, Haipeng;Li, Shenglan;Kim, Dong H.;Zhou, Hongxia;Xia, Xugang;Liu, Ying;Cao, Qilin
脊髓损伤(SCI)后的运动功能是评估康复的关键。目前，改善运动功能的有效手段包括手术、物理治疗、康复和外骨骼。神经前体细胞移植治疗干细胞是一种很有前途的修复策略。在这一点上，患者特异性诱导多能干细胞(IPSCs)是一种显著的自体细胞来源，它提供了许多优点，包括：产生同种异体移植的巨大潜力，避免了免疫抑制；可获得各种体细胞，而不存在与胚胎使用相关的伦理争议；以及大量分化。在这项工作中，为了实现IPSC-NPC治疗脊髓损伤的潜力，我们将纯化的IPSCs来源的NPC移植到颈椎挫伤大鼠模型中。我们的结果表明，IPSC-NPC能够存活并分化为神经元和星形胶质细胞，更重要的是，通过梳理任务和水平阶梯测试，改善了前肢的运动功能。纯化的IPSC-NPC代表了一种很有前途的细胞类型，可以进一步测试并发展成为临床上有用的细胞来源，用于颈部脊髓损伤患者的靶向细胞治疗。
Locomotor function after spinal cord injury (SCI) is critical for assessing recovery. Currently, available means to improve locomotor function include surgery, physical therapy rehabilitation and exoskeleton. Stem cell therapy with neural progenitor cells (NPCs) transplantation is a promising reparative strategy. Along this line, patient-specific induced pluripotent stem cells (iPSCs) are a remarkable autologous cell source, which offer many advantages including: great potential to generate isografts avoiding immunosuppression; the availability of a variety of somatic cells without ethical controversy related to embryo use; and vast differentiation. In this current work, to realize the therapeutic potential of iPSC-NPCs for the treatment of SCI, we transplanted purified iPSCs-derived NPCs into a cervical contusion SCI rat model. Our results showed that the iPSC-NPCs were able to survive and differentiate into both neurons and astrocytes and, importantly, improve forelimb locomotor function as assessed by the grooming task and horizontal ladder test. Purified iPSC-NPCs represent a promising cell type that could be further tested and developed into a clinically useful cell source for targeted cell therapy for cervical SCI patients.
登录
查看更多内容
影响因子：
5.9
作者：
Ito S;Nagoshi N;Kamata Y;Kojima K;Nori S;Matsumoto M;Takei K;Nakamura M;Okano H
通讯作者：
Okano H
影响因子：
4.8
作者：
Barak M;Fedorova V;Pospisilova V;Raska J;Vochyanova S;Sedmik J;Hribkova H;Klimova H;Vanova T;Bohaciakova D
通讯作者：
Bohaciakova D
影响因子：
3.6
作者：
Kajikawa K;Imaizumi K;Shinozaki M;Shibata S;Shindo T;Kitagawa T;Shibata R;Kamata Y;Kojima K;Nagoshi N;Matsumoto M;Nakamura M;Okano H
通讯作者：
Okano H
影响因子：
3.7
作者：
Kobayashi Y;Okada Y;Itakura G;Iwai H;Nishimura S;Yasuda A;Nori S;Hikishima K;Konomi T;Fujiyoshi K;Tsuji O;Toyama Y;Yamanaka S;Nakamura M;Okano H
通讯作者：
Okano H
DOI：
10.1523/jneurosci.3174-09.2010
发表时间：
2010-02-24
期刊：
The Journal of neuroscience : the official journal of the Society for Neuroscience
影响因子：
--
作者：
Cao Q;He Q;Wang Y;Cheng X;Howard RM;Zhang Y;DeVries WH;Shields CB;Magnuson DS;Xu XM;Kim DH;Whittemore SR
通讯作者：
Whittemore SR